Merck Sharp & Dohme Ltd.'s PD-1-targeting antibody Keytruda (pembrolizumab) has been added to the reimbursement list and launched in Japan for non-small cell lung cancer (NSCLC), and will provide the first direct rival in the immuno-oncology space to its already well established same-class competitor Opdivo (nivolumab).
Keytruda was added to the national health insurance tariff and launched on Feb. 15 for both first- and second-line use...